Aurobindo Pharma is largely an export oriented drug maker, while it does have an India business which is business-to-business (B2B) involving sale of active pharmaceutical ingredients to other drug makers. Aurobindo has net cash of $211 million as on December 2021. The drug maker is also in the process of restructuring its business which involves demerger of injectable business.
